Search company, investor...
CXR Biosciences company logo

CXR Biosciences

cxrbiosciences.com

Founded Year

2002

Stage

Acquired | Acquired

About CXR Biosciences

CXR Biosciences is an investigative toxicology business. The company provides expertise to international life sciences companies to help them resolve issues relating to the safety of compounds and with the selection of drug and chemical candidates.

Headquarters Location

2 James Lindsay Place Dundee Technopole

Dundee, Scotland, DD1 5JJ,

United Kingdom

+44 1382 432163

Missing: CXR Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: CXR Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

CXR Biosciences Patents

CXR Biosciences has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/18/2002

7/16/2013

Diabetes, Carboxylic acids, PPAR agonists, Perfluorinated compounds, Fluoroarenes

Grant

Application Date

2/18/2002

Grant Date

7/16/2013

Title

Related Topics

Diabetes, Carboxylic acids, PPAR agonists, Perfluorinated compounds, Fluoroarenes

Status

Grant

Latest CXR Biosciences News

Investors cash-in as CXR Biosciences sold

Aug 18, 2015

Investors cash-in as CXR Biosciences sold Niki McKenzie from Archangels. 0 comments A NUMBER of high profile Scottish investors have cashed in after CXR Biosciences was snapped up in what is believed to be a multi-million pound deal. The Dundee University spin-out, founded in 2001, works to evaluate the potential toxicity to humans of chemicals and compounds which are in the early stages of development. It operates in the pharmaceutical, agrochemical, consumer goods and oil and gas sectors. The entire share capital of CXR has now been bought by Concept Life Sciences, which is backed by private equity firm Equistone. Loading article content Investors listed on CXR’s most recent annual return include Sir Brian Souter, Ann Gloag, Mike Rutterford, Alistair Salvesen and other members of the Archangels investment syndicate. The document shows Scottish Enterprise is the single biggest shareholder with almost 15 per cent while CXR co-founder Clifford Elcombe has around 13 per cent of the business. Ms Gloag has almost 11 per cent with her younger brother Sir Brian owning more than five per cent of the shares. Mr Salvesen and Mr Rutterford have much smaller stakes. Dundee University owned 7.3 per cent of CXR. Promoted stories Archangels and Scottish Enterprise have supported CXR since its spin-out and with subsequent financing rounds over the years. Niki McKenzie, investment executive at Archangels, said: “This is a good deal for staff, for shareholders and for Scotland. CXR Biosciences is an excellent business and will benefit from being part of a larger life sciences group while retaining its base in Dundee. “This move reflects Archangels’ approach of investing early, providing support and further investment to allow our companies to grow and exiting at a mutually advantageous opportunity once they reach maturity. “We wish the business further success in the next chapter of the CXR story.” Kerry Sharp, head of the Scottish Investment Bank, said: “Over the last 10 years, we have worked closely with CXR Biosciences to provide an integrated package of support and investment including help with realising their international trade ambitions. “The acquisition by Concept Life Sciences allowing them to continue to operate in Dundee with the existing team is an optimal outcome.” All 33 staff at CXR are being retained with chief executive Paul Smith hailing the deal as a “natural next step” for the business in its growth plan. The company, where around half of the employees have PhD qualifications, will continue to be based in Dundee and retain its name. Mr Smith said: “Concept has really good backing. They want more and wider services. The don’t want the handle turning research, mandated by the regulator. They want the high science and problem solving end of it.” Mr Smith said Concept is supportive of CXR’s imminent move into dermal absorption testing and toxicology as well as additional new areas it is looking at. Asked whether this would mean additional staff in Dundee he said: “The first thing on the cards is the dermal services and we have a couple of other high science areas we are hoping to introduce to our pharmaceutical and agrochemical clients. “That will be agreed as we go on this. I’m sure there will be more expansion in Dundee.” Abbreviated accounts filed at Companies House show CXR made an after tax profit of more than £1.3 million in the 12 months to February 2014, from a loss of £533,340 in the previous year. Concept is understood to have been keen to expand its service offering and believes it can help CXR widen its client base further across Europe. It is the fourth acquisition Manchester based Concept has done since it was formed last year. It bought Peakdale Molecular, Resource & Environmental Consultants and Scientific Analysis Laboratories in what was described as a deal with a combined enterprise value of $100m. Scientific Analysis Laboratories has a site in East Kilbride while Resource & Environmental Consultants has offices in Aberdeen, Edinburgh and Glasgow. Concept’s executive chairman Michael Fort said: “Over the past year our group’s organic growth has been impressive. “We plan to continue to complement that growth with a series of carefully selected strategic acquisitions, thus adding significant value and expertise to the group. Share article “At the time of launch we laid out ambitious plans to build a comprehensive suite of niche, high-value, problem-solving services for our life science customer base. With the addition of market leading organisations such as CXR, we are more than achieving those plans. “We have identified a number of other complementary acquisitions, both in the UK and Europe, which we hope to execute during the remainder of 2015.” Promoted Stories

CXR Biosciences Frequently Asked Questions (FAQ)

  • When was CXR Biosciences founded?

    CXR Biosciences was founded in 2002.

  • Where is CXR Biosciences's headquarters?

    CXR Biosciences's headquarters is located at 2 James Lindsay Place, Dundee.

  • What is CXR Biosciences's latest funding round?

    CXR Biosciences's latest funding round is Acquired.

  • Who are the investors of CXR Biosciences?

    Investors of CXR Biosciences include Concept Life Sciences, Scottish Enterprise and Archangels Investors.

  • Who are CXR Biosciences's competitors?

    Competitors of CXR Biosciences include United BioSource, ADMA Biologics, Avantium Technologies, ThruPore Technologies, Biocrates Life Sciences and 13 more.

Compare CXR Biosciences to Competitors

P
Pacific Data Designs

ClinOps, LLC, is a focused contract research organization serving the Biotechnology, Pharmaceutical and Medical Device industries and specializes in data management, SAS/statistical analysis services, and investigatorinitiated study management. The company are committed to being a bestinclass partner to the company's clients by using the company's unparalleled core competencies to advance and accelerate their therapeutic clinical development initiatives.

Sai Life Sciences Logo
Sai Life Sciences

Sai Life Sciences offers their clients a wide range of integrated drug discovery, development and formulation services, with core expertise founded in synthetic, medicinal and process chemistry and further augmented by a suite of preclinical support services including DMPK, toxicology and formulation that are continually expanding to meet clients' needs.

M
Micromyx

Micromyx is a microbiology services company engaged in anti-infective discovery and development for the pharmaceutical, biotechnology, and animal health industries. Founded in 2004 by former pharmaceutical industry infectious disease scientists, Micromyx is a contract research organization that aims to offer clients documented, top-of-the-line laboratory services from experts who have successfully gained FDA approval of new antibiotics.

C
CRO services

CRO stands for Contract Research Organization, which takes part in clinical trial operations conducted by pharmaceutical companies or other entities. The company at TMRC Co., Ltd. provide monitoring, data management and other related operations engaged in cancers, to major pharmaceutical companies.

P
Progenix Research

Progenix Research is an independent contract research organisation offering toxicology services to the world-wide pharmaceutical, biotechnology, agrochemical and industrial chemical industries. It is a newly formed, independent contract research organisation with laboratory facilities currently under construction in Penang, Malaysia. The company's European headquarters are based in Malvern, England, and it also has a histopathology laboratory in Edinburgh, Scotland. A high quality, yet cost-efficient service for toxicology and associated studies will be offered, including studies on pharmaceuticals, biotechnology products, medical devices, food additives, agrochemicals, biocides, and speciality chemicals.

B
BioMedical Research Associates

BMRA aims to provide contract research services for medical device manufacturers, R&D groups, and other organizations requiring large or small animal models for device/drug applications and evaluations

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.